XTL Biopharmaceuticals Ltd. Sponsored ADR Stock

$1.10

4.75% yesterday

Nasdaq, May 20, 10:00 pm CET

ISIN

US98386D3070

Symbol

XTLB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

XTL Biopharmaceuticals Ltd. Sponsored ADR Stock price

$1.10

-0.21 16.03% 5Y

Nasdaq, Closing price Tue, May 20 2025

+0.05 4.75%

ISIN

US98386D3070

Symbol

XTLB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$13.80m
Enterprise Value	$12.80m
P/E (TTM) P/E ratio	negative
EV/Sales (TTM) EV/Sales	28.44
P/S ratio (TTM) P/S ratio	30.67
P/B ratio (TTM) P/B ratio	1.78
Revenue (TTM) Revenue	$450.00k
EBIT (operating result TTM) EBIT	$-2.17m
Cash position	$1.14m
EPS (TTM) EPS	$-0.11
Short interest	0.72%

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Get Started for Free Today

XTL Biopharmaceuticals Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast XTL Biopharmaceuticals Ltd. Sponsored ADR:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast XTL Biopharmaceuticals Ltd. Sponsored ADR:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from XTL Biopharmaceuticals Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	0.45 0.45	- 100%
- Direct Costs	0.45 0.45	- 100%
Gross Profit	- -	- -
- Selling and Administrative Expenses	2.08 2.08	185% 185% 462%
- Research and Development Expense	0.10 0.10	233% 233% 22%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-2.17 -2.17	184% 184% -483%
Net Profit	-1.03 -1.03	42% 42% -229%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

XTL Biopharmaceuticals Ltd. Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

about one month ago

XTL Names Mr. Noam Band as its New Chief Executive Officer

Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”) announced today the appointment of Noam Band as the Company's new Chief Executive Officer.

Company Profile

XTL Biopharmaceuticals Ltd. focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company was founded on March 9, 1993 and is headquartered in Raanana, Israel.

Head office	Israel
CEO	Noam Band
Employees	11
Founded	1993
Website	www.xtlbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now